Subscribe to RSS
DOI: 10.1055/s-0043-1770724
Effect of Oral Anticoagulants in Atrial Fibrillation Patients with Polypharmacy: A Meta-analysis
Funding This study was supported by the National Natural Science Foundation of China (82100273) and Guangdong Natural Science Foundation (2023A1515012798).
![](https://www.thieme-connect.de/media/10.1055-s-00035024/EFirst/lookinside/thumbnails/10-1055-s-0043-1770724_23010024-1.jpg)
Abstract
Background The aim of the present meta-analysis was to evaluate the effectiveness and safety of non-vitamin K antagonist oral anticoagulants (NOACs) versus vitamin K antagonists (VKAs) in atrial fibrillation (AF) patients with polypharmacy.
Methods and Results Randomized controlled trials or observational studies reporting the data of NOACs versus VKAs among AF patients with polypharmacy were included. The search was performed in the PubMed and Embase databases up to November 2022. A total of 12 studies involving 767,544 AF patients were included. For the primary outcomes, the use of NOACs compared with VKAs was significantly associated with a reduced risk of stroke or systemic embolism in AF patients with moderate polypharmacy (hazard ratio [HR]: 0.77 [95% confidence interval [CI]: 0.69–0.86]) and severe polypharmacy (HR: 0.76 [95% CI: 0.69–0.82]), but there was no significant difference in major bleeding (moderate polypharmacy: HR: 0.87 [95% CI: 0.74–1.01]; severe polypharmacy: HR: 0.91 [95% CI: 0.79–1.06]) between the two groups. In secondary outcomes, there were no differences in the rates of ischemic stroke, all-cause death, and gastrointestinal bleeding between the NOAC- and VKA- users, but NOAC users had a reduced risk of any bleeding compared with VKA- users. Compared with VKAs, the risk of intracranial hemorrhage was reduced in NOAC- users with moderate polypharmacy but not severe polypharmacy.
Conclusion In patients with AF and polypharmacy, NOACs showed advantages over VKAs in stroke or systemic embolism and any bleeding, and were comparable to VKAs for major bleeding, ischemic stroke, all-cause death, intracranial hemorrhage, and gastrointestinal bleeding.
Keywords
atrial fibrillation - non-vitamin K antagonist oral anticoagulants - vitamin K antagonists - polypharmacy - meta-analysisAuthors' Contribution
All authors listed have made a substantial, direct, and intellectual contribution to the work and approved it for publication.
* Co-first authors.
** Senior author.
The review process for this paper was fully handled by Christian Weber, Editor in Chief.
Publication History
Received: 28 January 2023
Accepted: 22 May 2023
Article published online:
03 July 2023
© 2023. Thieme. All rights reserved.
Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany
-
References
- 1 Kato ET, Goto S, Giugliano RP. Overview of oral antithrombotic treatment in elderly patients with atrial fibrillation. Ageing Res Rev 2019; 49: 115-124
- 2 Di Carlo A, Bellino L, Consoli D. et al; National Research Program: Progetto FAI. La Fibrillazione Atriale in Italia. Prevalence of atrial fibrillation in the Italian elderly population and projections from 2020 to 2060 for Italy and the European Union: the FAI Project. Europace 2019; 21 (10) 1468-1475
- 3 Masnoon N, Shakib S, Kalisch-Ellett L, Caughey GE. What is polypharmacy? A systematic review of definitions. BMC Geriatr 2017; 17 (01) 230
- 4 Connolly SJ, Ezekowitz MD, Yusuf S. et al; RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361 (12) 1139-1151
- 5 Giugliano RP, Ruff CT, Braunwald E. et al; ENGAGE AF-TIMI 48 Investigators. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2013; 369 (22) 2093-2104
- 6 Granger CB, Alexander JH, McMurray JJ. et al; ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365 (11) 981-992
- 7 Patel MR, Mahaffey KW, Garg J. et al; ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365 (10) 883-891
- 8 Eggebrecht L, Nagler M, Göbel S. et al. Relevance of polypharmacy for clinical outcome in patients receiving vitamin K antagonists. J Am Geriatr Soc 2019; 67 (03) 463-470
- 9 Jaspers Focks J, Brouwer MA, Wojdyla DM. et al. Polypharmacy and effects of apixaban versus warfarin in patients with atrial fibrillation: post hoc analysis of the ARISTOTLE trial. BMJ 2016; 353: i2868
- 10 Piccini JP, Hellkamp AS, Washam JB. et al. Polypharmacy and the efficacy and safety of rivaroxaban versus warfarin in the prevention of stroke in patients with nonvalvular atrial fibrillation. Circulation 2016; 133 (04) 352-360
- 11 Chao TF, Joung B, Takahashi Y. et al. 2021 Focused Update Consensus Guidelines of the Asia Pacific Heart Rhythm Society on Stroke Prevention in Atrial Fibrillation: executive summary. Thromb Haemost 2022; 122 (01) 20-47
- 12 Hindricks G, Potpara T, Dagres N. et al; ESC Scientific Document Group. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): the Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J 2021; 42 (05) 373-498
- 13 Fincke BG, Miller DR, Spiro III A. The interaction of patient perception of overmedication with drug compliance and side effects. J Gen Intern Med 1998; 13 (03) 182-185
- 14 By the 2019 American Geriatrics Society Beers Criteria® Update Expert Panel. American Geriatrics Society 2019 Updated AGS Beers Criteria® for potentially inappropriate medication use in older adults. J Am Geriatr Soc 2019; 67 (04) 674-694
- 15 Lip GYH, Keshishian A, Kang A. et al. Effectiveness and safety of oral anticoagulants among non-valvular atrial fibrillation patients with polypharmacy. Eur Heart J Cardiovasc Pharmacother 2021; 7 (05) 405-414
- 16 Harskamp RE, Teichert M, Lucassen WAM, van Weert HCPM, Lopes RD. Impact of polypharmacy and P-glycoprotein- and CYP3A4-modulating drugs on safety and efficacy of oral anticoagulation therapy in patients with atrial fibrillation. Cardiovasc Drugs Ther 2019; 33 (05) 615-623
- 17 Feng X, Sambamoorthi U, Innes K. et al. Predictors of major bleeding among working-age adults with atrial fibrillation: evaluating the effects of potential drug-drug interactions and switching from warfarin to non-vitamin K oral anticoagulants. Cardiovasc Drugs Ther 2018; 32 (06) 591-600
- 18 Brais C, Larochelle J, Turgeon MH. et al. Predictors of direct oral anticoagulants utilization for thromboembolism prevention in atrial fibrillation. J Pharm Pharm Sci 2017; 20: 8-14
- 19 Momo K, Shu-Toh K, Kaneko M. et al. Predictive factors associated with bleeding in atrial fibrillation patients treated with anti-coagulant drugs using a large claims database. PLoS One 2020; 15 (08) e0238233
- 20 Admassie E, Chalmers L, Bereznicki LR. Bleeding-related admissions in patients with atrial fibrillation receiving antithrombotic therapy: results from the Tasmanian Atrial Fibrillation (TAF) study. Eur J Clin Pharmacol 2017; 73 (12) 1681-1689
- 21 Jang BM, Lee OS, Shin EJ. et al. Factors related to inappropriate edoxaban use. J Clin Pharm Ther 2019; 44 (05) 760-767
- 22 Marco Garbayo JL, Koninckx Cañada M, Pérez Castelló I, Faus Soler MT, Perea Ribis M. Hospital admissions for bleeding events associated with treatment with apixaban, dabigatran and rivaroxaban. Eur J Hosp Pharm Sci Pract 2019; 26 (02) 106-112
- 23 Alberts MJ, He J, Kharat A, Ashton V. Effectiveness and safety of rivaroxaban versus warfarin among nonvalvular atrial fibrillation patients with obesity and polypharmacy. Am J Cardiovasc Drugs 2022; 22 (04) 425-436
- 24 Berger JS, Laliberté F, Kharat A. et al. Comparative effectiveness and safety of rivaroxaban and warfarin among nonvalvular atrial fibrillation (NVAF) patients with obesity and polypharmacy in the United States (US). Adv Ther 2021; 38 (07) 3771-3788
- 25 Chen N, Alam AB, Lutsey PL. et al. Polypharmacy, adverse outcomes, and treatment effectiveness in patients ≥75 with atrial fibrillation. J Am Heart Assoc 2020; 9 (11) e015089
- 26 Martinez BK, Baker WL, Sood NA. et al. Influence of polypharmacy on the effectiveness and safety of rivaroxaban versus warfarin in patients with nonvalvular atrial fibrillation. Pharmacotherapy 2019; 39 (02) 196-203
- 27 Mentias A, Heller E, Vaughan Sarrazin M. Comparative effectiveness of rivaroxaban, apixaban, and warfarin in atrial fibrillation patients with polypharmacy. Stroke 2020; 51 (07) 2076-2086
- 28 Millenaar D, Schumacher H, Brueckmann M. et al. Cardiovascular outcomes according to polypharmacy and drug adherence in patients with atrial fibrillation on long-term anticoagulation (from the RE-LY trial). Am J Cardiol 2021; 149: 27-35
- 29 van den Dries CJ, van Doorn S, Souverein P. et al. The number of concomitant drugs and the safety of direct oral anticoagulants in routine care patients with atrial fibrillation. TH Open 2020; 4 (04) e417-e426
- 30 Yamashita T, Akao M, Atarashi H. et al. Effect of polypharmacy on clinical outcomes in elderly patients with non-valvular atrial fibrillation - a sub-analysis of the ANAFIE registry. Circ J 2022; 87 (01) 6-16
- 31 Ruff CT, Giugliano RP, Braunwald E. et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 2014; 383 (9921): 955-962
- 32 Polzin A, Dannenberg L, Wolff G. et al. Non-vitamin K oral anticoagulants (NOAC) and the risk of myocardial infarction: differences between factor IIa and factor Xa inhibition?. Pharmacol Ther 2019; 195: 1-4
- 33 Hellwig T, Gulseth M. Pharmacokinetic and pharmacodynamic drug interactions with new oral anticoagulants: what do they mean for patients with atrial fibrillation?. Ann Pharmacother 2013; 47 (11) 1478-1487
- 34 Steffel J, Verhamme P, Potpara TS. et al; ESC Scientific Document Group. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J 2018; 39 (16) 1330-1393
- 35 Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther 2001; 23 (08) 1296-1310
- 36 Barnes GD, Nallamothu BK, Sales AE, Froehlich JB. Reimagining anticoagulation clinics in the era of direct oral anticoagulants. Circ Cardiovasc Qual Outcomes 2016; 9 (02) 182-185
- 37 Komen JJ, Pottegård A, Mantel-Teeuwisse AK. et al. Persistence and adherence to non-vitamin K antagonist oral anticoagulant treatment in patients with atrial fibrillation across five Western European countries. Europace 2021; 23 (11) 1722-1730